Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of APN1125 when administered as single doses to healthy adult subjects.

Key facts

Study ID

NCT02331433

Run by

CoMentis

People needed

58

Starts

2014-12-01

Expected to finish

2015-12-01

Last updated by the study team

2016-04-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males and females
• Aged 18 to 65 years, inclusive
• Body mass index (BMI) of 18 to 32kg/m\^2 inclusive at Screening
• Non-smoker or no tobacco/nicotine usage with 30 days of Screening

You may not qualify if…

• Personal or family history of neurological, cardiovascular, renal, hepatic, metabolic, gastrointestinal or endocrine abnormalities
• Any clinical abnormality in cardiovascular (e.g., blood pressure) or electrocardiogram (ECG) parameters at Screening and check-in

Where it is running

• PAREXEL Early Phase — Glendale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.